23andMe: Reza Afkhami

May 08, 2023

23andMe has named Reza Afkhami chief corporate development officer. In that role, he will oversee industry collaborations for the firm's therapeutics pipeline, research services, and consumer genomics operations. Afkhami joins 23andMe after serving as senior VP of corporate development and strategy at Global Blood Therapeutics while that firm was being acquired by Pfizer late last year.

Breaking News

Large Study of Early-Onset Colorectal Cancer Patients IDs Unique, Potentially Actionable Mutations
New Primate Genomes Study Deepens Understanding of Humans
People in the News at Illumina, Pacific Biosciences, Myriad Genetics, Delfi Diagnostics, More
New Products Posted to GenomeWeb: LabCorp, BostonGene, Seer, Myriad Genetics, More
Owkin, NanoString Technologies Launch $50M Spatial Omics Research Program for Cancer Research

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.